Molecular imaging of changes in the prevalence of vascular endothelial growth factor receptor in sunitinib-treated murine mammary tumors

Journal of Nuclear Medicine

Volumn 51, Issue 6, 2010, Pages 959-966

  Levashova, Zoia ^a   Backer, Marina ^b   Hamby, Carl V ^c   Pizzonia, John ^d   Backer, Joseph M ^b   Blankenberg, Francis G ^a  

^a STANFORD UNIVERSITY   (United States)

^b SIBTECH INC   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d Applications FUJIFILM Medical Systems USA Inc   (United States)

Author keywords

99mTcscVEGF; Imaging; SPECT; Sunitinib; Vegf receptors

Indexed keywords

BEVACIZUMAB; CD31 ANTIGEN; RADIOPHARMACEUTICAL AGENT; SINGLE CHAIN VASCULAR ENDOTHELIAL GROWTH FACTOR TC 99M; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 2; DIAGNOSTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; TECHNETIUM; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ARTICLE; AUTORADIOGRAPHY; BREAST TUMOR; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG RECEPTOR BINDING; DRUG UPTAKE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; ISOTOPE LABELING; MALE; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR MODEL; TUMOR VASCULARIZATION; ANIMAL; CHEMISTRY; DRUG ADMINISTRATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PROTEIN ENGINEERING; SCINTISCANNING; TIME; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD31; BIOLOGICAL TRANSPORT; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; MICE; MOLECULAR IMAGING; PROTEIN ENGINEERING; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TECHNETIUM; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77953953880     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.109.072199     Document Type: Article

References (40)

1. Jubb AM, Oates AJ, Holden S, Koeppen H. Predicting benefit from antiangiogenic agents in malignancy. Nat Rev Cancer. 2006;6:626-635.
2. Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique "window" of opportunity. Cancer Cell. 2004;6:529-531.
3. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006;3:24-40.
4. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008;8:579-591.
5. Bergers G, Hanahan D. Modes of resistance to antiangiogenic therapy. Nat Rev Cancer. 2008;8:592-603.
6. Ebos JML, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin Cancer Res. 2009;15:5020-5025.
7. Dempke WC, Heinemann V. Resistance to EGF-R (erbB-1) and VEGF-R modulating agents. Eur J Cancer. 2009;45:1117-1128.
8. Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol. 2008;5:378-391.
9. Backer MV, Levashova Z, Patel V, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF based probes. Nat Med. 2007;13:504-509.
10. Levashova Z, Backer M, Backer JM, Blankenberg FG. Direct labeling of Cys-tag in scVEGF with technetium 99m. Bioconjug Chem. 2008;19:1049-1054.
11. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9:327-337.
12. Levashova Z, Backer MV, Horng G, et al. SPECT and PET imaging of EGF receptor with site-specifically labeled EGF and dimeric EGF. Bioconjug Chem. 2009;20:742-749.
13. Ewan LC, Jopling HM, Jia H, et al. Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic. 2006;7:1270-1282.
14. Dougher M, Terman BI. Autophosphorylation of KDR in the kinase domain is required for maximal VEGF-stimulated kinase activity and receptor internalization. Oncogene. 1999;18:1619-1627.
15. Santos SC, Miguel C, Domingues I, et al. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res. 2007;313:1561-1574.
16. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic antivascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem. 2006;281:6625-6631.
17. Sloan B, Scheinfeld NS. Pazopnib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs. 2008;9:1324-1335.
18. Blankenberg FG, Levashova L, Sarkar SK, Pizzonia J, Backer MV, Backer JB. Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study. Transl Oncol. 2010;3:56-64.
19. Franco M, Man S, Chen L, et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res. 2006;66:3639-3648.
20. Palmowski M, Huppert J, Hauff P, et al. Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment. Cancer Res. 2008;68:7042-7049.
21. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574.
22. Bozec A, Gros FX, Penault-Llorca F, et al. Vertical VEGF targeting: a combination of ligand blockade with receptor tyrosine kinase inhibition. Eur J Cancer. 2008;44:1922-1930.
23. Selvakumaran M, Yao KS, Feldman MD, O'Dwyer PJ. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol. 2008;75:627-668.
24. Smith NR, James NH, Oakley I, et al. Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts. Mol Cancer Ther. 2007;6:2198-2208.
25. Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol. 2007;18(suppl 10):x3-x10.
26. Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA. 1997;94:8761-8766.
27. Mancuso MR, Davis R, Norberg SM. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116:2610-2621.
28. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008;26:1810-1816.
29. Johannsen M, Flörcken A, Bex A, et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol. 2009;55:1430-1438.
30. Reynolds AR, Hart IR, Watson AR, et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009;15:392-400.
31. Sakamaki K. Regulation of endothelial cell death and its role in angiogenesis and vascular regression. Curr Neurovasc Res. 2004;1:305-315.
32. Weinstein IB, Joe AK. Oncogene addiction. Cancer Res. 2008;68:3077-3080.
33. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-231.
34. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15:232-239.
35. Kerbel RS, Kamen BA. The anti-angiogenesis basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423-436.
36. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8:299-309.
37. Xiong YQ, Sun HC, Zhang W, et al. Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res. 2009;15:4838-4846.
38. Dudley AC, Klagsbrun M. Tumor endothelial cells join the resistance. Clin Cancer Res. 2009;15:4787-4789.
39. Loveless ME, Whisenant JG, Wilson K, et al. Coregistration of ultrasonography and magnetic resonance imaging with a preliminary investigation of the spatial colocalization of vascular endothelial growth factor receptor 2 expression and tumor perfusion in a murine tumor model. Mol Imaging. 2009;8:187-198.
40. Sargent DJ, Rubinstein L, Schwartz L, et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer. 2009;45:290-299.